EDNRB isoform 3 confers Temozolomide resistance in A375 melanoma cells by modulating membrane potential, reactive oxygen species and mitochondrial Ca2+
Yun Shan Chen,*,1 Fen Liu,*,1 Yi Hong Luo,1 Yue Fan,1 Fang Gui Xu,1 Pin Li,1 Bei Zhou,1 Xiu Yu Pan,1 Chi Chiu Wang,2–4 Long Cui1,41Department of Obstetrics and Gynaecology, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou 510623, Guangdong, P...
Main Authors: | Chen YS, Liu F, Luo YH, Fan Y, Xu FG, Li P, Zhou B, Pan XY, Wang CC, Cui L |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2019-08-01
|
Series: | Cancer Management and Research |
Subjects: | |
Online Access: | https://www.dovepress.com/ednrb-isoform-3-confers-temozolomide-resistance-in-a375-melanoma-cells-peer-reviewed-article-CMAR |
Similar Items
-
Alternative temozolomide dosing regimens and novel combinations for the treatment of advanced metastatic melanoma
by: Wen-Jen Hwu, et al.
Published: (2011-12-01) -
Is Autophagy Inhibition in Combination with Temozolomide a Therapeutically Viable Strategy?
by: Ahmed M. Elshazly, et al.
Published: (2023-02-01) -
Multi-Omics Analyses Reveal Mitochondrial Dysfunction Contributing to Temozolomide Resistance in Glioblastoma Cells
by: Huaijin Zhang, et al.
Published: (2023-09-01) -
A Phase I Study of High-Dose Calcitriol in Combination with Temozolomide for Patients with Metastatic Melanoma
by: Erin Pettijohn, et al.
Published: (2014-10-01) -
Multimodality Treatment in the Management of Anorectal Melanoma: A Case Report and Review of the Literature
by: Umit Tapan, et al.
Published: (2011-12-01)